IXICO Members of the Alzheimer’s Disease Neuroimaging Initiative

May 29, 2013
News

IXICO, Ltd. announced today that they are now official Private Partner Scientific Board (PPSB) members of the Alzheimer’s Disease Neuroimaging Initiative (ADNI). As a participant, IXICO will help the Consortium achieve its goals in better understanding and defining the devastating effects of Alzheimer’s Disease (AD).

London, England – 29th October, 2012

IXICO, Ltd. announced today that they are now official Private Partner Scientific Board (PPSB) members of the Alzheimer’s Disease Neuroimaging Initiative (ADNI). As a participant, IXICO will help the Consortium achieve its goals in better understanding and defining the devastating effects of Alzheimer’s Disease (AD).

ADNI is a key research initiative of the Foundation for the National Institutes of Health (FNIH) and works by tracking normal, mildly cognitively impaired (MCI), and Alzheimer’s disease brain changes with medical imaging such as PET and MRI to measure the progression of dementia. The PPSB serves as an independent, open, and pre-competitive forum for all private-sector partners in ADNI to collaborate, share information, and offer scientific perspectives and expertise on issues relating to the project. This collaboration nurtures emerging knowledge and is building upon a database that will provide better tools for carrying out effective clinical trials and identify biomarkers that can predict clinical outcome.

“With its main focus on various biochemical and imaging biomarkers for detection and monitoring of AD pathophysiology, ADNI is opening up new pathways for the development of diagnostics and therapeutics for this devastating disease. In particular, the Industry group of the ADNI effort (the PPSB), has realized the huge benefits of the collaborative nature of the consortium in providing an excellent forum for aligning pre-competitive activities between pharmaceutical, diagnostic and medical imaging companies.” Said Johan Luthman, Chair of the PPSB. “We are therefore extremely happy to see the medical imaging company IXICO joining the PPSB; the company's knowledge in applied imaging brings critical expertise and competence to the work of the ADNI community."

ADNI has, in fact, led to improved understanding of how to conduct such trials in a multi-centre setting by employing imaging technologies to analyze blood and cerebrospinal fluid biomarkers. As a result, pharmaceutical companies developing Alzheimer’s disease drugs have begun using ADNI methodologies in their clinical trials. The idea is that by using drugs to treat validated biomarkers of Alzheimer’s disease instead of treating less-precise cognitive measures, the cost and length of drug trials can be reduced, bringing effective treatment to the world quicker and more cheaply.

Michael Weiner, Director of ADNI added “I welcome the medical imaging company IXICO to the ADNI family. We are dedicated to improving treatment and clinical trials leading to effective therapies for AD.  The expertise of the IXICO scientists will bring new ideas and energy to our work".

Kate McLeish, VP of Technology at IXICO said “We are delighted to be an official member of the PPSB and look forward to collaborating to advance the understanding of dementia to support those developing drugs to treat patients.”

Already, more than 400 investigators from across the world have accessed ADNI data for their own analyses. The study has also fostered similar projects in Australia, Japan, Europe and China. Additional projects are being discussed in Korea, India and South America. The establishment of worldwide standards and a worldwide network for clinical trials has huge implications for the scientific community.

Launched in 2004, ADNI was scheduled to conclude in late 2010.Owing to the great success of the project, ADNI II has been initiated which will continue the ADNI study to late 2015. ADNI II will continue to track the current ADNI subjects and will enroll additional normal, mildly cognitively impaired, and Alzheimer’s disease patients, as well as people with early or very mild cognitive impairment. Furthermore, Additional imaging modalities will be employed including functional MRI (fMRI), Arterial Spin Labelling (ASL) and Diffusion Tensor Imaging (DTI).

Current ADNI PPSB members include:

  • Abbott
  • Alzheimer’s Association
  • Alzheimer’s Drug Discovery Foundation
  • Amorfix Life Sciences
  • AstraZeneca
  • Bayer HealthCare
  • BioClinica
  • Biogen Idec
  • Bristol-Myers Squibb
  • Canadian Institutes of Health Research
  • Eisai, Inc.
  • Elan Pharmaceuticals
  • Eli Lilly and Company
  • GE Healthcare
  • Genentech
  • Innogenetics
  • IXICO
  • Janssen Alzheimer Immunotherapy
  • Johnson & Johnson
  • Medpace
  • Merck
  • Meso Scale Diagnostics
  • Novartis Pharmaceuticals
  • Pfizer, Inc.
  • Roche
  • Servier
  • Synarc
  • Takeda

 

About the FNIH

Established by the United States Congress to support the mission of the NIH—improving health through scientific discovery in the search for cures—the Foundation for the NIH is a leader in identifying and addressing complex scientific and health issues. The Foundation is a non-profit, charitable organization that raises private-sector funds for a broad portfolio of unique programs that complement and enhance the NIH priorities and activities. ADNI is one suck key research initiative of the FNIH.